TROG 95.01 - Rectal Cancer - TROG Cancer Research

By w.paterson
15 August, 2021
0 Comments

A Randomised Trial Comparing Adjuvant Protracted Venous Infusion and Bolus 5FU/Leucovorin with Either Early or Late Radiotherapy in Rectal Caner

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

TOPGEAR trial results published in the New England Journal of Medicine

18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

11 September, 2024

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

11 September 2024: Our 2024 Annual Scientific Meeting was

Join us to raise $35,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Randomised Trial Comparing Adjuvant Protracted Venous Infusion and Bolus 5FU/Leucovorin with Either Early or Late Radiotherapy in Rectal Caner

TROG 95.02 – Proctitis – Rectal Sucralfate

TROG 94.01/AGITG IG9401 – Oesophagus – Localised Resectable (IG9401)

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000

TROG 95.01 – Rectal Cancer

A Randomised Trial Comparing Adjuvant Protracted Venous Infusion and Bolus 5FU/Leucovorin with Either Early or Late Radiotherapy in Rectal Caner

TROG 95.02 – Proctitis – Rectal Sucralfate

TROG 94.01/AGITG IG9401 – Oesophagus – Localised Resectable (IG9401)

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000